| Literature DB >> 35557740 |
Abstract
Asparagine (N)-linked protein glycosylation is a ubiquitous co- and posttranslational modification which has a huge impact on the biogenesis and function of proteins and consequently on the development, growth, and physiology of organisms. In mammals, N-glycan processing carried out by Golgi-resident glycosidases and glycosyltransferases creates a number of structurally diverse N-glycans with specific roles in many different biological processes. In plants, complex N-glycan modifications like the attachment of β1,2-xylose, core α1,3-fucose, or the Lewis A-type structures are evolutionary highly conserved, but their biological function is poorly known. Here, I highlight recent developments that contribute to a better understanding of these conserved glycoprotein modifications and discuss future directions to move the field forward.Entities:
Keywords: glycan; glycoprotein; glycosylation; posttranslational modification; secretory pathway
Year: 2022 PMID: 35557740 PMCID: PMC9085483 DOI: 10.3389/fpls.2022.897549
Source DB: PubMed Journal: Front Plant Sci ISSN: 1664-462X Impact factor: 5.753
Figure 1(A) Illustration of the processing pathway for the formation of complex N-glycans in plants. GCSI, α-glucosidases I (GCSI); GCSII, α-glucosidases II; MNS3, ER α-mannosidase; GMI, Golgi α-mannosidase I (two forms termed MNS1 and MNS2 with redundant function are present in Arabidopsis thaliana); GNTI, β1,2-N-acetylglucosaminyltransferase I; GMII, Golgi α-mannosidase II; GNTII, β1,2-N-acetylglucosaminyltransferase II; XYLT, β1,2-xylosyltransferase; FUT, core α1,3-fucosyltransferases (two forms termed FUT11 and FUT12 with redundant function are present in A. thaliana); GALT1, Lewis type β1,3-galactosyltransferase; and FUT13, α1,4-fucosyltransferase. Not shown: the removal of terminal GlcNAc residues by β-hexosaminidases, which generates paucimannosidic N-glycans in post-Golgi compartments, at the plasma membrane or in the extracellular space. (B) Illustration of typical complex, hybrid, and paucimannosidic N-glycans. (C) Illustration of the predominate N-glycan structure of the indicated knockout mutants. Alternative names of the mutants are given in brackets. Symbols are used according to the suggestions from the Consortium for Functional Glycomics (http://www.functionalglycomics.org/).
Overview of phenotypes in vascular plants with aberrant N-glycans.
| Species | Gene | Technology | Phenotype | Reference |
|---|---|---|---|---|
|
|
| T-DNA | Altered root morphology | |
|
| EMS/T-DNA | No obvious phenotype | ||
|
| T-DNA | No obvious phenotype | ||
|
| T-DNA | Altered growth under stress | ||
|
| T-DNA | No obvious phenotype | ||
|
| T-DNA | No obvious phenotype | ||
|
| T-DNA | No obvious phenotype | ||
|
|
| T-DNA | Reduced growth, altered seed set | |
|
| Gamma-ray | Plant growth affected under various stresses, affected seed germination | ||
|
| T-DNA | Pollen viability affected | ||
|
| T-DNA | Developmental abnormalities | ||
|
| CRISPR/Cas9 | No phenotype in callus | ||
|
|
| LORE1 retrotransposon | Reduced growth | |
|
| LORE1 retrotransposon | Severe growth defect, lethality | ||
|
| LORE1 retrotransposon | Reduced growth | ||
|
|
| RNAi | No obvious phenotype | |
|
|
| CRISPR/Cas9 | No obvious phenotype | |
|
| CRISPR/Cas9 | No obvious phenotype | ||
|
| CRISPR/Cas9 | No obvious phenotype | ||
|
| RNAi | No obvious phenotype | ||
|
|
| antisense | No obvious phenotype | |
|
|
| CRISPR/Cas9 | No obvious phenotype | |
|
|
| CRISPR/Cas9 | No obvious phenotype | |
|
| CRISPR/Cas9 | No obvious phenotype | ||
|
|
| RNAi | Abnormal fruit ripening | |
|
|
| RNAi | Fewer, enlarged seeds | |
|
|
| antisense | No obvious phenotype |
N-glycan processing defects of Golgi located enzymes are listed.
This indicates the technology used to generate the mutants.
For mutants with various phenotypes, only some characteristic phenotypes are shown.